Does Strong Early Waldenström Data Redraw The Bull Case For Nurix Therapeutics' Degrader Platform (NRIX)? [Yahoo! Finance]
Nurix Therapeutics, Inc. - Common stock (NRIX)
Company Research
Source: Yahoo! Finance
with relapsed or refractory Waldenström macroglobulinemia, with mostly low-grade side effects supporting further development. This early signal suggests Nurix's targeted protein degradation platform could offer a differentiated approach in a difficult-to-treat blood cancer setting. Next, we'll explore how this promising Waldenström macroglobulinemia efficacy signal shapes Nurix's investment narrative and perceived pipeline potential. Outshine the giants: these 24 early-stage AI stocks could fund your retirement To own Nurix Therapeutics, you really have to believe in its targeted protein degradation platform and its ability to turn early clinical signals into durable, registrational programs, despite ongoing losses and a rich valuation. The new Waldenström macroglobulinemia data with bexobrutideg fits cleanly into that story: a 75% response rate and manageable safety add credibility to BTK degradation and could sharpen investor focus on the DAYBreak CLL program and upcoming AS
Show less
Read more
Impact Snapshot
Event Time:
NRIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRIX alerts
High impacting Nurix Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
NRIX
News
- Wells Fargo Reaffirms a Buy Rating on Nurix Therapeutics (NRIX), Sets a $30 PT [Yahoo! Finance]Yahoo! Finance
- Nurix Therapeutics (NRIX): Revisiting Valuation After a 120% Three-Month Share Price Surge [Yahoo! Finance]Yahoo! Finance
- Nurix Therapeutics (NASDAQ:NRIX) had its price target raised by analysts at Wells Fargo & Company from $21.00 to $30.00. They now have an "overweight" rating on the stock.MarketBeat
- Nurix Therapeutics (NASDAQ:NRIX) had its price target raised by analysts at Mizuho from $24.00 to $30.00. They now have an "outperform" rating on the stock.MarketBeat
- Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
NRIX
Earnings
- 10/9/25 - Miss
NRIX
Sec Filings
- 12/18/25 - Form 4
- 12/18/25 - Form 144
- 12/9/25 - Form 8-K
- NRIX's page on the SEC website